SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation is a commercial-stage healthcare company that develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. Its offerings include the selective cytopheretic device (SCD), a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm causing destructive hyperinflammation, and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. The company also develops NEUTRALIZE-AKI, an SCD therapy in clinical trials for adult patients with AKI, and other products in therapeutic areas such as cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. Founded in 2007, SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.